Transcenta Holding Limited states that it has received the green light from FDA to continue with TranStar 301,This trial is conducted for Osemitamab (TST001) used together with Nivolumab and chemotherapy.

Time to Next Treatment (TTNT) is defined as the period from the start of the treatment to the start of the next line of treatment.

The October release of the Patsnap Bio Sequence Database provides a plethora of enhancements in order to improve your searching experience and elevate the efficiency of your FTO review.

This article summarized the latest R&D progress of dexmedetomidine hydrochloride, the Mechanism of Action for dexmedetomidine hydrochloride, and the drug target R&D trends for dexmedetomidine hydrochloride.

Syndax Pharmaceuticals has reported encouraging preliminary figures following a protocol-defined collective examination of the essential AUGMENT-101 study on revumenib, a front-runner in the class of menin inhibitors.

Determining the effectiveness, safety, and marketability of a drug requires validation through clinical trials.

Menin is an expression product of the tumorigenic gene MEN1 in multiple endocrine neoplasia.

This article summarized the latest R&D progress of dexchlorpheniramine maleate, the Mechanism of Action for dexchlorpheniramine maleate, and the drug target R&D trends for dexchlorpheniramine maleate.

SOLA Biosciences is set to share its promising preliminary proof-of-concept data for SOL-257, a specific gene therapy aimed at misfolded TDP-43 in ALS.

This article summarized the latest R&D progress of dermatan sulfate, the Mechanism of Action for dermatan sulfate, and the drug target R&D trends for dermatan sulfate.

Vertex Pharmaceuticals Incorporated presented extensive data related to the patients treated in sections A and B of their Phase 1/2 clinical assessment trial of VX-880.

This article summarized the latest R&D progress of darifenacin hydrobromide, the Mechanism of Action for darifenacin hydrobromide, and the drug target R&D trends for darifenacin hydrobromide.